Government Affairs
Refine Search
Pharmaceutical
The US Food and Drug Administration yesterday announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use. 'Too many people suffer unnecessary injuries from avoidable medication misuse, errors and other problems. The FDA is launching the Safe Use Initiative to develop targeted solutions for reducing these injuries,' said FDA Commissioner Margaret Hamburg. 5 November 2009
Pharmaceutical
European policymakers and the pharmaceutical industry need to work collaboratively to ensure the current financial crisis does not stand in the way of delivering health care systems fit for the 21st century. Representatives of the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing research-based drugmakers in Europe, and Members of the European Parliament involved in health care issues discussed a common agenda to shape the future of health care in Europe this week 5 November 2009
Pharmaceutical
The French government is planning to push through a dual pricing system for pharmaceutical products, designed to clamp down on the lucrative export of drugs to other European countries, reports Andrew Jack in the UK's Financial Times. The move would squeeze "parallel trade," the widespread and legal practice within the European Union by which arbitragers buy medicines where they are available cheaply and sell them where they cost more. 4 November 2009
Biotechnology
Three of the leading biotech clusters in France are joining forces to harness the potential of stem cells for the development of health care advances. The new consortium has received significant government funding for a three-year R&D project, which will focus on the use of iPSCs, or induced pluripotent stem cells. 4 November 2009
Biotechnology
The USA's Biotechnology Industry Organization (BIO) issued the following statement in response to a letter recently sent by the Generic Pharmaceutical Association (GPhA) to the White House requesting the Obama Administration to urge Congressional leaders to strike biosimilars provisions from health care reform legislation unless the provisions are 'materially altered' (The Pharma Letter October 30): 3 November 2009
Pharmaceutical
Although not as devastating as expected, the cuts by the USA's Centers for Medicare and Medicaid Services (CMS) will still decrease reimbursements far beyond what the US cancer care delivery system, including most patients, can bear, says the Community Oncology Alliance (COA), and are a move in the wrong direction of health care reform. 3 November 2009
Generics
The UK improved its position by one place, and is now ranked fifth of the nine Western European markets surveyed in Business Monitor International's Business Environment Ratings (BER) for the fourth quarter of 2009. 3 November 2009
Pharmaceutical
October 30, 2009
Pharmaceutical sales in Colombia reached 4,466 billion Colombian pesos ($2.27bn) in 2008, according to a new report from Business Monitor International. This represents impressive growth of 11.4% in local currency terms between 2007 and 2008 (compared with a 3.2% decline in the drug market between 2006 and 2007). 30 October 2009
Pharmaceutical
The South African Treasury has made significant additions to the government's budget for HIV/ AIDS programs in anticipation of meeting its target of providing treatment to 80% of those in need by 2011, says the nation's Business Day. 29 October 2009
Generics
Ecuador's President Rafael Correa this week declared access to priority medicines affecting the health of the Ecuadorean population to be a matter of public interest. Under Andean Community law, the declaration opens the door to competition from generic medicines with patented brand-name drugs, through the use of compulsory licensing. The declaration could lead to government policies that expand access to medicines. 29 October 2009
Biotechnology
French President Nicolas Sarkozy has offered his public support for the country's biotechnology industry by creating InnoBio and pledging funds of 139 million euros ($208.5 million) to the sector. 29 October 2009
Pharmaceutical
Australia's Pharmaceutical Benefits (PBS) scheme is a robust policy instrument with which none of the government's many health reviews has identified a systemic problem, trade group Medicines Australia chairman Will Delaat told the country's National Press Club yesterday. 29 October 2009
Generics
Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) yesterday called for the enactment of la aw prescribing stiffer penalties for drug counterfeiters. It asked the nation to emulate China's approach to the battle against fake drugs, reports the local Vanguard newspaper. 28 October 2009
Pharmaceutical
The European Commission has renewed its efforts to fight HIV/AIDS in the European Union and neighboring countries by adopting a strategy for the period 2009-2013. Effective HIV treatment exists but there is still no cure or vaccine against AIDS. 28 October 2009
Pharmaceutical
A report issued October 26 by the USA's Government Accountability Office (GAO) has criticized the Food and Drug Administration for not following up on studies for some drugs that get approved after data suggest they are effective on a marker that stands in for the course of disease. 27 October 2009
Pharmaceutical
As US lawmakers debate health care reform, business innovator Lou Weisbach and Clinton White House health care advisor Richard Boxer say that they see a glaring, missing element of the forthcoming health care legislation: reducing health care costs - and saving lives - by preventing and curing disease. 27 October 2009
Pharmaceutical
October 26, 2009
According to a new snapshot into the future of the Australian drug funding system, compiled by the Centre for Strategic Economic Studies, the country's Pharmaceutical Benefits System reforms would deliver A$6.4 billion ($5.9 billion) total savings over 10 years - A$3 billion more than the Government's estimate. 26 October 2009
Pharmaceutical
Following a request to the USA's Government Accountability office to review the Food and Drug Administration's debarment and disqualification processes, it has reached the conclusions that the agency is slow to debar health professionals who have been convicted of crimes from doing research for the agency or overseeing the safety of patients in clinical trials, according to the government watchdog's report released Thursday. 23 October 2009
Biotechnology
US President Barack Obama has now signed into law the fiscal 2010 Agriculture Appropriations Bill. This was passed by a large margin in the House of Representatives on October 7 and the Senate followed suit on October 8. 23 October 2009
Pharmaceutical
The latest edition from Research and Markets' Clinical Trials Special Report Series breaks down China's clinical trials landscape and analyze the government investments that are making the country more attractive for inclusion in global drug development programs of pharma companies of all sizes. 23 October 2009
Pharmaceutical
The nomination of Robert F Kennedy Jr — known as RFK Jr — for the role of US Secretary of the Department of Health and Human Services (HHS) President-elect Donald Trump sent shares in vaccine companies sharply downwards. 22 November 2024
article
The UK government has reappointed BioIndustry Association (BIA) chairman Daniel Mahony as its Life Sciences Investment Envoy. 21 November 2024
Pharmaceutical
The Danish government’s newly-unveiled health reform has been praised for tackling chronic disease care and health inequalities while driving health innovation. 18 November 2024
Pharmaceutical
New research published by the European Federation of Pharmaceutical Industries and Associations (EFPIA) provides in-depth analysis of the economic footprint of the pharmaceutical industry in Europe, across member states and compares Europe to other regions of the world. 18 November 2024
Pharmaceutical
Johnson & Johnson has taken legal action to defend a contentious rebate initiative, filing a lawsuit in the US District Court for the District of Columbia. 15 November 2024
Pharmaceutical
The share prices of Pfizer, GSK, Novavax and other vaccine companies were all markedly lower on Friday. This was not due to the publication of disappointing research results in the sphere, or an ominous stance taken by a major regulator on a key filing, but rather a political development that could spell trouble for the vaccines field as a whole. 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Danish patients are being offered fewer innovative treatments than Norwegians and Swedes, a new estimate from the Danish Medicines Council shows. 11 November 2024
Pharmaceutical
According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research investments. 11 November 2024
Pharmaceutical
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director general of Danish Medicines Agency, have signed a letter of intent to promote bilateral cooperation in regulation of drugs and medical devices. 11 November 2024
Pharmaceutical
Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie Utterback has published a new note about the impact of this on the managed-care industry. 7 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Some of the UK’s leading academics and industry professionals have welcomed Chancellor Rachel Reeves’ £520 million ($669 million) pledge to develop the country’s medicine manufacturing capabilities. 6 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
The Danish government is rolling out the red carpet and welcomes several pharmaceutical companies. 4 November 2024
Generics
Medicines for Europe has launched a study of market barriers faced by European generics and biosimilar pharmaceutical companies operating in 11 key third-country markets. 31 October 2024
Pharmaceutical
Following the first Labour budget for 14 years, the Association of the British Pharmaceutical Industry (ABPI) welcomes Chancellor Rachel Reeves’ measures to improve UK life sciences competitiveness. 30 October 2024
Pharmaceutical
HOPO Therapeutics has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA). 29 October 2024
Pharmaceutical
The Danish government has presented part of the plan for a future life science strategy, which has been welcomed by the industry. 28 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze